Navigation Links
The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority
Date:4/1/2011

WHITE PLAINS, N.Y., April 1, 2011 /PRNewswire/ -- Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

But for many cancers, such as the blood cancers, early detection is rare, there are no measures that can be taken to prevent the onset of the disease, and they are still killing too many. In these cases, the only solution is continued research to find better treatments and cures once the diagnosis is made.

It is for this reason that many voluntary disease organizations have created programs to accelerate therapies from laboratories to patients. We recognize that funding research is costly and difficult, particularly in these trying economic times, particularly for orphan diseases such as blood cancers where producing these treatments may not always be cost-effective for drug companies.

We have to be more proactive and innovative in our approaches to funding drug development, not only funding laboratory research, but also partnering with biotechnology companies on high-prospect research projects, or by providing much needed expertise to help academics bring their discoveries to market.  We are continually searching for new ways to ensure that scientific discoveries are not stuck collecting dust on academic shelves, but are given the boost they need to cross the chasm that swallows so many promising findings.

The Federal government also recognizes this need to get more treatments to patients faster.  A key provision of the federal Affordable Care Act that has received little attention is the creation by Congress of the Cures Acceleration Network (CAN). This program, which would be administered by Frances Collins, Ph.D.,
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
4. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
5. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
6. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
7. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. The Leukemia & Lymphoma Society and The International Waldenstroms Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research
10. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
11. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Providerâ„¢ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, Inc. ... in connection with the acquisition of Durata Therapeutics, Inc. ... connection with the termination of PDL,s credit agreement with ... outstanding of $40 million, accrued interest, and prepayment and ... into a structured financing transaction with Durata in which ...
(Date:11/17/2014)... 17, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today the formation of a Medical Advisory Board ... Company as it advances the Phase 3 clinical ... of cutaneous T-cell lymphoma (CTCL), a rare class ...
(Date:11/15/2014)... 2014 The redesigned ActiGraph Link ... and sleep measurement platform with a rich feature ... with multiple new channels of sensor data captured ... with Bluetooth Smart technology, the ActiGraph Link supports ... uploads to ActiGraph’s cloud-based Study Admin platform, giving ...
Breaking Biology Technology:Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6ActiGraph Launches GT9X Link Activity Monitor 2
... ... ... ... , ...
... ... for different body types and shampoo bottles shaped to closely match the size of ... to redesign armor for troops in Afghanistan. , ... Madison, NJ, USA (PRWEB) February 24, 2010 -- Interactive exhibits make learning ...
... ... ... , ... , , , , ...
Cached Biology Technology:Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 2Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 3Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 4Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 5Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 6Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 7Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 2Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
(Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... Information Network Studies (CWINS) at Worcester Polytechnic Institute (WPI) ... National Institute of Standards and Technology (NIST) to conduct ... around and through the human body. Led by Kaveh ... of CWINS, the research will help speed the development ...
... from the Robertson Foundation to create a state-of-the-art Translational ... cell therapy research and treatment programs for children and ... suffered at birth. In making the announcement, Victor J. ... Chief Executive Officer for Duke University Health System, said ...
... the world will be at the Marriott in Walnut ... Institute 5th Annual Genomics of Energy and Environment Meeting, ... clean energy generation and the environment. Keynote speeches will ... Joint BioEnergy Institute, Steve Pennell of Ceres Inc. on ...
Cached Biology News:WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3DOE Joint Genome Institute 5th Annual Meeting on March 24-26, 2010 2
... The BD PhosFlow Perm/Wash Buffer I ... post-translationally modified signaling proteins to permeabilize cells ... and cell wash buffer. Because saponin-mediated cell ... important to keep the cells in the ...
Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
... The user-friendly Eppendorf Thermomixer R ... preparations that require shaking, heating, and ... greatly expanded its application and temperature ... can each accommodate 24 micro test ...
Biology Products: